Eli Lilly Phase 3b data showed an improvement in the efficacy of Taltz and Zepbound in the treatment of psoriatic arthritis and obesity over a period of one year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.